
LONZA GROUP AG

ISIN: CH0013841017 WKN: 1384101

Overview





Information about previous performance does not guarantee future performance. **Source:** FactSet


Recent research

| on sector on mar | ket | | |
|------------------|---------------------|-----------------------|----------|
| Date | | Headline | Download |
| 2024/04/26 | 80 F8 82 F8 | Global Equity Ratings | .≛. |
| 2024/04/03 | 80 J.26 87 J.78 | Global Equity Ratings | |
| 2024/03/13 | 80 52 82 188 | Global Equity Ratings | |
| 2024/02/22 | 80 J.26 87 J.58 | Global Equity Ratings | |
| 2024/02/14 | 80 72 27 180 | Global Equity Ratings | |



Details





Information about previous performance does not guarantee future performance. **Source:** FactSet

| Price data | |
|---|-----------------------|
| Ø price 5 days Ø volume 5 days (pcs.) | 294.00 - (140) |
| Ø price 30 days Ø volume 30 days (pcs.) | 288.24 - (190) |
| Ø price 100 days Ø volume 100 days (pcs.) | 271.65 - (174) |
| Ø price 250 days Ø volume 250 days (pcs.) | 267.96 - (214) |
| YTD High date | 302.60 - (2019/06/20) |
| YTD Low date | 223.90 - (2019/01/02) |
| 52 Weeks High date | 302.60 - (2019/06/20) |
| 52 Weeks Low date | 216.00 - (2018/12/27) |



Company profile

Company Logo



Contact Details

LONZA GROUP AG

- -

Muenchensteinerstrasse 38 - 4002 Basel

Telefon: +41-61-316-81-11 Fax: +41-61-316-91-11 E-mail: media@lonza.com

PDF Downloads

Company report: LONZA GROUP AG



Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment offers small molecule drug substances and intermediates related services. The Cell and Gene segment includes the Cell and Gene Technologies and Bioscience businesses. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.

| Members of Management Board | | | | |
|-----------------------------|-------------------------------|--|--|--|
| Albert M. Baehny | Chairman of Managing Board | | | |
| Christian Seufert | Member of Executive Committee | | | |
| Daniel Palmacci | Member of Executive Committee | | | |
| Gordon Bates | Member of Executive Committee | | | |
| Jean-Christophe Hyvert | Member of Executive Committee | | | |
| Maria Soler Nunez | Member of Executive Committee | | | |
| Philippe Deecke | Member of Executive Committee | | | |
| Ulrike Kaeppler | Member of Executive | | | |

Committee

| Board of direc | tors |
|-------------------------|------------------------------------|
| Angelica Kohlmann | Member of the administrative board |
| Marion Helmes | Member of the administrative board |
| Olivier Verscheure | Member of the administrative board |
| Roger Nitsch | Member of the administrative board |
| Barbara Richmond | Member of the administrative board |
| Christoph Mäder | Member of the administrative board |
| Jürgen B. Steinemann | Member of the administrative board |

